PFG Investments LLC Trims Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

by · The Markets Daily

PFG Investments LLC lessened its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 386,447 shares of the biotechnology company’s stock after selling 9,800 shares during the quarter. PFG Investments LLC owned 0.65% of Aldeyra Therapeutics worth $2,083,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter worth approximately $38,000. Diversified Trust Co purchased a new position in shares of Aldeyra Therapeutics during the second quarter worth $41,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter valued at $49,000. Laidlaw Wealth Management LLC grew its stake in shares of Aldeyra Therapeutics by 32.6% in the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 4,150 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Aldeyra Therapeutics by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 2,729 shares during the period. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, August 9th.

Check Out Our Latest Research Report on Aldeyra Therapeutics

Aldeyra Therapeutics Stock Down 0.9 %

Shares of ALDX stock opened at $5.33 on Friday. The firm has a 50 day moving average of $5.60 and a two-hundred day moving average of $4.49. The stock has a market capitalization of $316.38 million, a PE ratio of -10.44 and a beta of 1.44. Aldeyra Therapeutics, Inc has a 52 week low of $1.46 and a 52 week high of $6.55.

About Aldeyra Therapeutics

(Free Report)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

Featured Articles